Long-term remission of Kaposi's sarcoma following foscarnet treatment in HIV-infected patients.
Five patients with HIV-associated Kaposi's sarcoma (epidemic KS) were treated with foscarnet 180 mg/kg/day i.v. for 10 days. Four of them suffered from severe immunodeficiency with CD4 cell counts below 30 x 10(6)/l. Three of the patients went into long-term remission of KS. One patient was free of relapse for 12 months and 2 patients are still in remission after an observation period of 13 and 20 months respectively. The results suggest a possible role of foscarnet in the treatment of epidemic KS.
Morfeldt
L
L
Division of Infectious Diseases, Karolinska Institute, Danderyd Hospital, Sweden.
Torssander
J
J
D000328:Adult; D017245:Foscarnet / Q000627:therapeutic use*; D015658:HIV Infections / Q000150:complications*; D018451:Homosexuality, Male; D006801:Humans; D008297:Male; D008875:Middle Aged; D010157:Palatal Neoplasms / Q000188:drug therapy*; D010865:Pilot Projects; D012074:Remission Induction; D012514:Sarcoma, Kaposi / Q000188:drug therapy*; D012878:Skin Neoplasms / Q000188:drug therapy*; D013997:Time Factors
D017245:Foscarnet